Chris Leiter
@chrisleiter_
Followers
1K
Following
6K
Media
31
Statuses
977
funding the frontiers of biology + human health @ Atria Ventures 🧬 bio/acc
46.564501, 7.896697
Joined August 2008
Excited to share for the first time what I've been building at @atriaVC - investing in the next generation of founders in AI + biology at pre-seed and seed. If you're building, it's never too early to start a conversation. DMs are open.
Biotech venture capital is on the precipice of a generational shift. At least, that’s according to the crowd of younger firm founders edging their way in.
19
13
165
Distibution. Distribution. Distribution. One of the biggest misses I see in early stage deeptech bio companies is a fundamental lack of awareness of distribution. Focusing on customer discovery, showing a deep understanding of needs and unique insights in the market is gold.
This is why I'll sometimes invest in B-tier tech with A-tier growth strategies, especially if I believe the CEO can become A-tier over time. But. Here's the kicker—the point of this whole thread:. Founders NEVER talk about distribution in their decks.
1
0
11
RT @shelbynewsad: What if computationally designed enzymes in the future are all multi-step? . Eg - they have multiple active sites for dif….
0
16
0
RT @MichaelRetchin: Can we connect pharma R&D to commercial teams (and vice versa) for smarter drug development?. I'm excited to host the "….
0
7
0
This was a fun event to host with the @bitsinbio crew - complete with the first live public demo of @EvoscaleAI's ESM3 protein model! . Big thank you to our co-hosts @8vc & @fjeg1987.
A huge thank you to everyone who came out to last night's @bitsinbio Showcase Event in San Francisco. It was an incredible evening of connecting with the biotech/techbio community, learning about the latest advances in the field from startups (including an ESM3 demo) to industry
1
0
5
Learning to fail, fast and early in life, is an incredibly underrated superpower.
0
0
8
. There’s no difference. Then it was called deep learning, and that got people really excited. And then artificial intelligence.”. @MorganStanley predicts big pharma will spend $50BN a year in the coming year on AI-enabled drug development. But what is real today?.
0
0
0
Atoms, agents and transformers - AI x Bio summit 2023 is a wrap. Huge shoutout to @NYSE for hosting us!
1
0
30
The American dream feeds on perpetual, exceptional optimism.
0
0
2
Phenomenal contribution to the techbio canon by @ameekapadia @pablolubroth and many others. A must read.
Really excited to launch the first edition of the Decoding Bio Snapshot—a journey into the trends and companies operating where computation meets bio
0
0
5
A prescient reminder that pharma is almost always pro-cyclical when it comes to M&A. Not convinced that the vast wasteland of struggling publics will drive M&A (even firesale). Immense value destruction in the coming quarters.
Amongst big pharma deals that exceeded >$1B in 2022, EV / 2026 revenue was 7.1x. That willingness to pay is one signal that the supply of suitable M&A targets is smaller than appreciated, despite the record # of biotech companies (1/x).
0
0
2
join us before @SynBioBeta for all things decentralized science next Monday w/ our friends @fiftyyears @Molecule_dao @paulkhls.
Join us at the @fiftyyears HQ in San Francisco for an evening of food and conversation with a community of scientists, blockchain devs, and biotech VCs.. What if we could crowdfund all biomedical research? How can we enable research funding for neglected diseases? How can we
0
2
15
Very early data (20-person cohort) suggests GLP-1s (e.g. Ozempic/semaglutide, Mounjaro/tirzepatide) rehabilitate natural killer cells independent of weight loss function - the same NK cells that kill cancer.
0
0
18
0
0
0
mismatch: pharma/biotech VC funding vs. global health needs
9
6
41